版本:
中国

BRIEF-Oncomed Pharma reports new data presented at American Association for Cancer Research

April 5 Oncomed Pharmaceuticals Inc:

* Oncomed Pharma-phase 1b study data of tarextumab in extensive-stage small cell lung cancer show changes in ctcs appear to correlate with os outcomes

* Oncomed Pharma- in series of preclinical studies, anti-rspo3 with paclitaxel chemo showed synergistic anti-tumor activity in tumors with rspo3 translocations

* Oncomed Pharma- preparing to file ind application with U.S. FDA during first half of 2017 for its novel gitrl-fc trimer immuno-oncology agent Source text for Eikon: Further company coverage:

我们的标准: 汤森路透“信任原则

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐